Kymera Therapeutics (KYMR) Stock Analysis & AI Equity Report
Kymera Therapeutics (KYMR) overview
Kymera Therapeutics (KYMR) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 39.2m and operating profit of USD -349m; the year-end share price was 77.81 USD and market capitalisation was USD 6,328m. Kymera Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Kymera Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Kymera Therapeutics
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing oral medicines for human diseases. Its research focuses on targeted protein degradation and other small molecule approaches, with current programs primarily directed at immunology targets including STAT6, IRF5, and IRAK4. The company also has research initiatives in other therapeutic areas. Its intended beneficiaries are patients with serious diseases, including immune-inflammatory conditions.
Generate the Kymera Therapeutics report
Kymera Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Kymera Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Kymera Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.